Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial.
Hiroki TeragawaTakeshi MorimotoYuichi FujiiTomohiro UedaMio SakumaMichio ShimabukuroOsamu ArasakiKoichi NodeTakashi NomiyamaShinichiro UedaPublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2020)
In this sub-analysis from the REASON Trial, taking a DPP-4 inhibitor, either ANA or SITA, for 52 weeks did not affect the levels of inflammatory markers.